(MLYS) Mineralys Therapeutics - Ratings and Ratios
Hypertension, Mineralocorticoid, Receptor, Antagonist, Therapy
MLYS EPS (Earnings per Share)
MLYS Revenue
Description: MLYS Mineralys Therapeutics
Mineralys Therapeutics, Inc. is a biotechnology company listed on NASDAQ under the ticker symbol MLYS. The companys common stock is traded in the US market, and its market capitalization stands at approximately $962.61 million.
As a biotech firm, Mineralys Therapeutics is likely to be involved in the development of innovative treatments or therapies, which can be a high-risk, high-reward business. The industry is characterized by significant R&D expenses, regulatory hurdles, and the potential for substantial returns if products gain approval and achieve market success.
Key economic drivers for Mineralys Therapeutics include the progress of its product pipeline, the outcome of clinical trials, and the potential for FDA approvals. The companys financial performance will be influenced by its ability to manage R&D expenses, secure funding, and achieve commercial success with its products.
From a financial perspective, the companys return on equity (ROE) is negative, at -70.44%, indicating that it is currently unprofitable. This is not uncommon for biotech companies, which often require significant investments in R&D before generating revenue. The price-to-earnings (P/E) ratio is not available, likely due to the companys negative earnings.
To evaluate the companys prospects, investors may focus on key performance indicators (KPIs) such as cash runway, R&D milestones, and pipeline progress. Other relevant metrics could include the companys burn rate, the number of patients enrolled in clinical trials, and the competitive landscape for its products.
From a trading perspective, the stocks beta is -0.300, indicating a negative correlation with the overall market. This suggests that the stock may be less volatile than the broader market, but it also implies that it may not be a straightforward play on market trends. The average trading volume is substantial, at over 782,000 shares per day, indicating a reasonable level of liquidity.
MLYS Stock Overview
| Market Cap in USD | 2,787m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2023-02-10 |
MLYS Stock Ratings
| Growth Rating | 58.2% |
| Fundamental | 29.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 163% |
| Analyst Rating | 4.75 of 5 |
MLYS Dividends
Currently no dividends paidMLYS Growth Ratios
| Growth Correlation 3m | 59.7% |
| Growth Correlation 12m | 56.4% |
| Growth Correlation 5y | -0.4% |
| CAGR 5y | 37.25% |
| CAGR/Max DD 3y | 0.54 |
| CAGR/Mean DD 3y | 1.18 |
| Sharpe Ratio 12m | 0.44 |
| Alpha | 192.86 |
| Beta | 0.850 |
| Volatility | 122.87% |
| Current Volume | 1705.6k |
| Average Volume 20d | 1302.8k |
| Stop Loss | 33.6 (-7.2%) |
| Signal | -0.18 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-190.8m TTM) > 0 and > 6% of Revenue (6% = 2040 TTM) |
| FCFTA -0.50 (>2.0%) and ΔFCFTA -24.08pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.57 (>3.0%) and CFO -192.7m <= Net Income -190.8m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 15.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (65.5m) change vs 12m ago 32.61% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.01% (prev 0.0%; Δ 0.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -19.24
| (A) 0.93 = (Total Current Assets 335.3m - Total Current Liabilities 22.2m) / Total Assets 335.7m |
| (B) -1.16 = Retained Earnings (Balance) -388.0m / Total Assets 335.7m |
| warn (B) unusual magnitude: -1.16 — check mapping/units |
| (C) -0.48 = EBIT TTM -156.3m / Avg Total Assets 327.1m |
| (D) -17.50 = Book Value of Equity -388.0m / Total Liabilities 22.2m |
| Total Rating: -19.24 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 29.13
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -6.15% = -3.07 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.07 = 2.50 |
| 5. Debt/Ebitda -0.14 = -2.50 |
| 6. ROIC - WACC -66.85% = -12.50 |
| 7. RoE -70.44% = -2.50 |
| 8. Rev. Trend 30.57% = 2.29 |
| 9. EPS Trend -1.68% = -0.08 |
What is the price of MLYS shares?
Over the past week, the price has changed by +0.78%, over one month by +149.38%, over three months by +169.22% and over the past year by +212.16%.
Is Mineralys Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MLYS is around 34.10 USD . This means that MLYS is currently overvalued and has a potential downside of -5.83%.
Is MLYS a buy, sell or hold?
- Strong Buy: 6
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MLYS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 40.8 | 12.5% |
| Analysts Target Price | 40.8 | 12.5% |
| ValueRay Target Price | 38.2 | 5.6% |
Last update: 2025-09-10 04:43
MLYS Fundamental Data Overview
CCE Cash And Equivalents = 101.8m USD (Cash And Short Term Investments, last quarter)
P/B = 8.8888
Beta = -0.296
Revenue TTM = 34.0k USD
EBIT TTM = -156.3m USD
EBITDA TTM = -156.3m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 22.2m USD (from totalCurrentLiabilities, last quarter)
Debt = 22.2m USD (Calculated: Short Term 22.2m + Long Term 0.0)
Net Debt = -101.8m USD (from netDebt column, last quarter)
Enterprise Value = 2.71b USD (2.79b + Debt 22.2m - CCE 101.8m)
Interest Coverage Ratio = unknown (Ebit TTM -156.3m / Interest Expense TTM 0.0)
FCF Yield = -6.15% (FCF TTM -166.4m / Enterprise Value 2.71b)
FCF Margin = -489.4k% (FCF TTM -166.4m / Revenue TTM 34.0k)
Net Margin = -561.1k% (Net Income TTM -190.8m / Revenue TTM 34.0k)
Gross Margin = -26.47% ((Revenue TTM 34.0k - Cost of Revenue TTM 43.0k) / Revenue TTM)
Tobins Q-Ratio = -6.98 (set to none) (Enterprise Value 2.71b / Book Value Of Equity -388.0m)
Interest Expense / Debt = 7.56% (Interest Expense 1.68m / Debt 22.2m)
Taxrate = 21.0% (US default)
NOPAT = -156.3m (EBIT -156.3m, no tax applied on loss)
Current Ratio = 15.12 (Total Current Assets 335.3m / Total Current Liabilities 22.2m)
Debt / Equity = 0.07 (Debt 22.2m / last Quarter total Stockholder Equity 313.6m)
Debt / EBITDA = -0.14 (Net Debt -101.8m / EBITDA -156.3m)
Debt / FCF = -0.13 (Debt 22.2m / FCF TTM -166.4m)
Total Stockholder Equity = 270.8m (last 4 quarters mean)
RoA = -56.82% (Net Income -190.8m, Total Assets 335.7m )
RoE = -70.44% (Net Income TTM -190.8m / Total Stockholder Equity 270.8m)
RoCE = -57.73% (Ebit -156.3m / (Equity 270.8m + L.T.Debt 0.0))
RoIC = -57.73% (NOPAT -156.3m / Invested Capital 270.8m)
WACC = 9.12% (E(2.79b)/V(2.81b) * Re(9.15%)) + (D(22.2m)/V(2.81b) * Rd(7.56%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 25.93%
Discount Rate = 9.15% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -166.4m)
EPS Correlation: -1.68 | EPS CAGR: 0.0% | SUE: 0.36 | # QB: False
Revenue Correlation: 30.57 | Revenue CAGR: 0.0%
Additional Sources for MLYS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle